| Literature DB >> 23445637 |
Hamisi M Malebo1, Tanja Wenzler, Monical Cal, Sauda M Swaleh, Maurice O Omolo, Ahmed Hassanali, Urs Séquin, Daniel Häussinger, Petur Dalsgaard, Matthias Hamburger, Reto Brun, Isaiah O Ndiege.
Abstract
BACKGROUND: Malaria, trypanosomiasis and leishmaniasis have an overwhelming impact in the poorest countries in the world due to their prevalence, virulence and drug resistance ability. Currently, there is inadequate armory of drugs for the treatment of malaria, trypanosomiasis and leishmaniasis. This underscores the continuing need for the discovery and development of new anti-protozoal drugs. Consequently, there is an urgent need for research aimed at the discovery and development of new effective and safe anti-plasmodial, anti-trypanosomal and anti-leishmanial drugs.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23445637 PMCID: PMC3599822 DOI: 10.1186/1472-6882-13-48
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Figure 1Chemical structures of isolated compounds.
Anti-plasmodial activity (IC) and cytotoxicity (CC) of HSCCC fractions of methanolic leaf extract
| AKLM | 15,000 | 0.12 ± 0.01 | 30.0 ± 0.8 | 250 | 1.9 | 60 | 3,333 |
| AKLM1 | 562 | 5.0 ± 0.31 | >90.0 | >18 | 79.4 | 2500 | >10,000 |
| AKLM2 | 2,999 | 0.87 ± 0.1 | 20.0 ± 3.3 | 23 | 13.8 | 435 | 2,222 |
| AKLM3 | 1,534 | 3.01 ± 0.81 | 78.0 ± 5.4 | 26 | 47.8 | 1,505 | 8,667 |
| AKLM 4 | 157 | 1.34 ± 0.33 | 76.0 ± 1.44 | 57 | 21.3 | 670 | 8,444 |
| AKLM 5 | 249 | 3.6 ± 0.2 | >90.0 | >25 | 57.1 | 1,800 | >10,000 |
| AKLM 6 | 427 | 0.45 ± 0.15 | 59.0 ± 1.5 | 131 | 7.1 | 225 | 6,556 |
| AKLM 7 | 165 | 0.11 ± 0.02 | >90.0 | >818 | 1.7 | 55 | >10,000 |
| AKLM 8 | 221 | 0.09 ± 0.04 | >90.0 | >1,000 | 1.4 | 45 | >10,000 |
| AKLM 9 | 680 | 0.06 ± 0.02 | >90.0 | >1,500 | 1.0 | 30 | >10,000 |
| AKLM 10 | 1,295 | 0.05 ± 0.02 | >90.0 | >1,800 | 0.8 | 25 | >10,000 |
| AKLM 11 | 1,679 | 0.05 ± 0.01 | >90.0 | >1,800 | 0.8 | 25 | >10,000 |
| AKLM 12 | 1,056 | 0.06 ± 0.03 | >90.0 | >1,500 | 1.0 | 30 | >10,000 |
| AKLM 13 | 878 | 0.62 ± 0.4 | >90.0 | >145 | 9.8 | 310 | >10,000 |
| AKLM 14 | 948 | 1.0 ± 0.22 | >90.0 | >90 | 15.9 | 500 | >10,000 |
| AKLM 15 | 1,232 | 0.13 ± 0.02 | >90.0 | >692 | 2.1 | 65 | >10,000 |
| AKLM 16 | 416 | 0.09 ± 0.03 | 84.0 ± 3.91 | 933 | 1.4 | 45 | 9,333 |
| AKLM 17 | 498 | 1.67 ± 0.43 | >90.0 | >54 | 26.5 | 835 | >10,000 |
Fr. – HSCCC fraction of Annickia kummeriae leaves methanolic extract, P. falciparum K1 used for anti-plasmodial assays, rat myoblast L-6 cells used for cytotoxicity assays, CQ chloroquine (IC50 0.063 ± 0.034 μg/ml), Art artemisinin (IC50 0.002 ± 0.00001 μg/ml), Pdx podophyllotoxin (IC50 0.009 ± 0.003 μg/ml).
Anti-plasmodial activity (IC) and cytotoxicity (CC) data of sub-fractions of fraction 2 of methanolic leaf extract
| AKLM 2 | 2,500 | 0.90 ± 0.11 | 21.0 ± 3.87 | 23.3 | 14 | 450 | 3,500 |
| AKLM 2.1 | 15.3 | 5.0 ± 1.31 | >90 | 18.0 | 78 | 2,500 | >15,000 |
| AKLM 2.2 | 26.9 | 1.09 ± 0.26 | 79.1 ± 7.60 | 72.6 | 17 | 545 | 13,183 |
| AKLM 2.3 | 57.6 | 4.11 ± 0.29 | 53.1 ± 9.20 | 12.9 | 64 | 2,055 | 8,850 |
| AKLM 2.4 | 98.7 | 1.16 ± 0.18 | 13.8 ± 1.80 | 11.9 | 18 | 580 | 2,300 |
| AKLM 2.5 | 126.1 | 3.63 ± 0.04 | 24.6 ± 3.30 | 6.8 | 57 | 1,815 | 4,100 |
| AKLM 2.6 | 115.7 | 1.23 ± 0.31 | 39.5 ± 2.20 | 32.1 | 19 | 615 | 6,583 |
| AKLM 2.7 | 239.0 | 3.41 ± 0.48 | 85.4 ± 4.60 | 25.0 | 53 | 1,705 | 14,233 |
| AKLM 2.8 | 478.3 | 5.0 ± 0.53 | >90 | 18.0 | 78 | 2,500 | >15,000 |
| AKLM 2.9 | 351.8 | 2.40 ± 0.57 | 56.7 ± 8.00 | 23.6 | 38 | 1,200 | 9,450 |
| AKLM 2.10 | 301.9 | 0.89 ± 0.20 | 35.3 ± 5.31 | 39.7 | 14 | 445 | 5,883 |
| AKLM 2.11 | 672.8 | 0.64 ± 0.34 | 44.7 ± 4.45 | 69.8 | 10 | 320 | 7,450 |
HSCCC High speed counter current chromatography; AKLM Annickia kummeriae leaf methanol extract, P. falciparum K1 used for anti-plasmodial assays, rat myoblast L-6 cells used for cytotoxicity assays, CQ chloroquine (IC50 0.063 ± 0.034 μg/ml), Art - artemisinin (IC50 0.002 ± 0.00001 μg/ml), Pdx - podophyllotoxin (IC50 0.009 ± 0.003 μg/ml).
Anti-protozoal activity (IC) and cytotoxicity (CC) data of alkaloids from
| | |||||||
|---|---|---|---|---|---|---|---|
| Lysicamine ( | 2.4 ± 0.642 | 1.5 | 3.7 ± 0.001 | 2.3 | 2.7 ± 0.001 | 1.7 | 1.6 ± 0.01 |
| Trivalvone ( | 1.6 ± 0.232 | 28.3 | 14.3 ± 0.001 | 3.2 | 2.9 ± 0.001 | 15.6 | 45.3 ± 0.02 |
| Palmatine ( | 0.080 ± 0.001 | 1,154 | 3.2 ± 0.004 | 28.1 | 7.8 ± 0.001 | 11.5 | >90 |
| Jatrorrhizine ( | 0.24 ± 0.002 | 375.0 | 4.2 ± 0.002 | 21.4 | 20.4 ± 0.03 | 4.4 | >90 |
| Jatrorrhizine ( | 0.14 ± 0.017 | 358.6 | 4.0 ± 0.001 | 12.6 | 13.1 ± 0.02 | 3.8 | 50.2 ± 0.08 |
| Palmatine ( | 0.098 ± 0.002 | 629.6 | 4.3 ± 0.005 | 14.4 | 7.0 ± 0.06 | 8.81 | 61.7 ± 0.01 |
P. falciparum – K1 strain, T. b. rhodesiense – STIB 900 strain, L. donovani - MHOM-ET-67/L82, L-6 - rat skeletal myoblast cells, IC50 – inhibitory concentration for 50% of tested parasites, CC50 – cytotoxic concentration for 50% of tested cells, chloroquine IC50 0.063 ± 0.03, artemisinin IC50 0.002 ± 0.0001, melarsoprol IC50 0.002 ± 0.0001, miltefosine IC50 0.11 ± 0.001, podophyllotoxin IC50 0.009 ± 0.0003.
Comparison of anti-protozoal activity (IC) and cytotoxicity (CC) of alkaloids from with standard drugs
| Lysicamine ( | 38.1 | 1,200.0 | 1,850.0 | 23.6 | 177.8 |
| Trivalvone ( | 25.4 | 800.0 | 7,150.0 | 26.4 | 5,033.3 |
| Palmatine ( | 1.3 | 40.0 | 1,600.0 | 70.9 | >10,000 |
| Jatrorrhizine ( | 3.8 | 120 | 2,100.0 | 185.5 | >10,000 |
| Jatrorrhizine ( | 2.2 | 69.0 | 2,000.0 | 119.1 | 5,577.8 |
| Palmatine ( | 1.6 | 49.0 | 2,150.0 | 63.64 | 6,855.6 |
Cpd isolated compound, CQ chloroquine, Art artemisinin, Mel melarsoprol, Pdx podophyllotoxin.